Weight Loss Outcomes Among Early High Responders to Exenatide Treatment: A Randomized, Placebo Controlled Study in Overweight and Obese Women.

Abstract

Objective:

As there is significant heterogeneity in the weight loss response to pharmacotherapy, one of the most important clinical questions in obesity medicine is how to predict an individual's response to pharmacotherapy. The present study examines patterns of weight loss among overweight and obese women who demonstrated early robust response to twice daily exenatide treatment compared to those treated with hypocaloric diet and matched placebo injections.

Methods:

We randomized 182 women (BMI 25-48 kg/m2) to treatment with exenatide alone or matched placebo injections plus hypocaloric diet. In both treatment groups, women who demonstrated ≥ 5% weight loss at 12 weeks were characterized as high responders and those who lost ≥10% of body weight were classified as super responders. Our primary outcome was long-term change in body weight among early high responders to either treatment. An exploratory metabolomic analysis was also performed.

Results:

We observed individual variability in weight loss with both exenatide and hypocaloric diet plus placebo injections. There was a trend toward a higher percentage of subjects who achieved ≥ 5% weight loss with exenatide compared to diet (56% of those treated with exenatide, 76% of those treated with diet, p = 0.05) but no significant difference in those who achieved ≥ 10% weight loss (23% of individuals treated with exenatide and 36% of those treated with diet, p = 0.55). In both treatment groups, higher weight loss at 3 months of treatment predicted super responder status (diet p=0.0098, exenatide p=0.0080). Both treatment groups also demonstrated similar peak weight loss during the study period. We observed lower cysteine concentrations in the exenatide responder group (0.81 vs 0.48 p < 0.0001) and a trend toward higher levels of serotonin, aminoisobutyric acid, anandamide, and sarcosine in the exenatide super responder group.

Conclusion:

In a population of early high responders, longer term weight loss with exenatide treatment is similar to that achieved with a hypocaloric diet.

Clinical Trial Registration:

www.clinicaltrialsgov, identifier NCT01590433.

• Authors: Megan Rodgers, Alexandra L Migdal, Tahereh Ghorbani Rodríguez, Zsu-Zsu Chen, Anjali K Nath, Robert E Gerszten, Natasha Kasid, Elena Toschi, Juliet Tripaldi, Brent Heineman, Minh Phan, Long Ngo, Eleftheria Maratos-Flier, Jody Dushay
• Journal: Frontiers in endocrinology (Front Endocrinol (Lausanne)) Vol. 12 Pg. 742873 ( 2021) ISSN: 1664-2392 [Print] Switzerland
• PMID: 34867786 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2021 Rodgers, Migdal, Rodríguez, Chen, Nath, Gerszten, Kasid, Toschi, Tripaldi, Heineman, Phan, Ngo, Maratos-Flier and Dushay.

Chemical References

• Anti-Obesity Agents
• Exenatide
• Cysteine

Topics

• Adult
• Anti-Obesity Agents (therapeutic use)
• Body Mass Index
• Combined Modality Therapy
• Cysteine (metabolism)
• Diet, Reducing
• Double-Blind Method
• Exenatide (therapeutic use)
• Female
• Humans
• Metabolomics
• Middle Aged
• Obesity (drug therapy)
• Overweight (drug therapy)
• Treatment Outcome
• Weight Loss